In a recent study published in the December 15th issue of Human Molecular Genetics, Dr. Gangwani and his team of researchers at TTUHSC El Paso describe how mice with spinal
muscular atrophy saw great improvement when the JNK3 enzyme was genetically inhibited to eliminate its activity.
Not exact matches
The first and newest FDA - approved treatment of nusinersen doesn't completely cure the disease, so Sumner's research team wanted to
see if using ASO - A in conjunction with nusinersen would further improve muscle form and function in mice with spinal
muscular atrophy.
The finding suggests that patients with spinal
muscular atrophy could also
see improvement if treated with a drug that suppresses the activity of JNK3.
«Families and advocates are very pleased to
see the advancement of this antisense technology for the treatment of spinal
muscular atrophy.
The Patient Advisory Group of the International Coordinating Committee (ICC) for SMA Clinical Trials has published a family - friendly set of guidelines for care in spinal
muscular atrophy (SMA)-- click here to download the guide — to complement the physician guidelines published in August (for more on the physicians» consensus statement,
see The Journal of -LSB-...]
The Patient Advisory Group of the International Coordinating Committee (ICC) for SMA Clinical Trials has published a family - friendly set of guidelines for care in spinal
muscular atrophy (SMA)-- click here to download the guide — to complement the physician guidelines published in August (for more on the physicians» consensus statement,
see The Journal of Child Neurology.)
Genetic testing is available for you to
see if you or your partner carry genes for Cystic Fibrosis, Sickle Cell, Spinal
Muscular Atrophy and other disease that may affect your decision making.